

Supporting Information

Ruthenium-Catalyzed Direct C-3
Oxidative Olefination of
Imidazo[1,2-a]pyridines

Haiying Zhan,^a Limin Zhao, ^{*a} Naiying Li,^a Shuxian Qiu,^a

Longbin Chen,^a Jingyun Liu,^a Jinqiang Liao^a and Hua Cao^a

^a*School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical
University, Guangzhou 510006, P.R. of China;*

E-mail: caohua@gdpu.edu.cn,

A. General method

^1H and ^{13}C NMR spectra were recorded using a Bruker Avance 400 MHz NMR spectrometer. The chemical shifts are referenced to signals at 7.26 and 77.0 ppm, respectively, chloroform is solvent with TMS as the internal standard. Elemental analyses were performed with a Vario EL elemental analyzer. TLC was performed by using commercially prepared 100–400 mesh silica gel plates (GF254) and visualization was effected at 254 nm. All the other chemicals were purchased from Aldrich Chemicals, Alfa Aesar and Acros Chemical.


B. General Procedure

Synthesis of 4a according to the following procedure:

2-methylimidazo[1,2-a]pyridine (**1a** 0.5 mmol), ethyl acrylate (**2a** 2.5 mmol), 3 mol% $[\text{RuCl}_2(\text{p-cymene})]_2$, $\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}$ (1.0 mmol), 40 mol% AgSbF_6 , were added in anhydrous DCE (3 mL) at room temperature. And then the mixture was stirred at 120 °C under air for 24 h. After completion of the reaction, water (8 mL) was added. The aqueous solution was extracted with diethyl ether (3×15 mL), and the combined extract was dried with anhydrous MgSO_4 . Solvent was removed, and the crude product was separated by column chromatography (eluted with petroleum ether : ethyl acetate=2:1) to give a pure sample of **3aa**.


C. Analytical data

(2E)-ethyl 3-(2-methylH-imidazo[1,2-a]pyridin-3-yl)acrylate (3aa)




^1H NMR (400 MHz, CDCl_3): δ 8.34 (d, $J = 6.8$ Hz, 1H), 7.97 (d, $J = 16.1$ Hz, 1H), 7.65 (d, $J = 8.9$ Hz, 1H), 7.36 – 7.31 (m, 1H), 6.99 (t, $J = 6.8$ Hz, 1H), 6.26 (d, $J = 16.1$ Hz, 1H), 4.32 (q, $J = 7.1$ Hz, 2H), 2.66 (s, 3H), 1.38 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 167.7, 146.2, 128.9, 126.3, 124.3, 121.1, 117.3, 113.7, 113.0, 60.6, 15.6, 14.4. MS (EI) m/z (%): 230, 185, 158, 78, 51; ESI-MS m/z (%) 231 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{13}\text{H}_{14}\text{N}_2\text{O}_2$: C, 67.81; H, 6.13; N, 12.17; Found: C, 67.95; H, 5.52; N, 12.97;

(2E)-methyl 3-(2-methylH-imidazo[1,2-a]pyridin-3-yl)acrylate (3ab)




^1H NMR (400 MHz, CDCl_3): δ 8.31 (d, $J = 6.8$ Hz, 1H), 7.95 (d, $J = 16.1$ Hz, 1H), 7.62 (d, $J = 9.0$ Hz, 1H), 7.34 – 7.29 (m, 1H), 6.97 (t, $J = 6.8$ Hz, 1H), 6.24 (d, $J = 16.1$ Hz, 1H), 3.84 (s, 3H), 2.63 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 168.0, 148.8, 146.4, 129.1, 126.2, 124.2, 120.3, 117.3, 113.5, 112.2, 51.7, 15.6. ESI-MS m/z (%) 217 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{12}\text{H}_{12}\text{N}_2\text{O}_2$: C, 66.65; H, 5.59; N, 12.96; Found: C, 66.56; H, 5.56; N, 13.04;

(2E)-butyl 3-(2-methylH-imidazo[1,2-a]pyridin-3-yl)acrylate (3ac)




^1H NMR (400 MHz, CDCl_3): δ 8.31 (d, $J = 6.8$ Hz, 1H), 7.95 (d, $J = 16.1$ Hz, 1H), 7.61 (d, $J = 8.9$ Hz, 1H), 7.29 (d, $J = 9.7$ Hz, 1H), 6.96 (s, 1H), 6.24 (d, $J = 16.1$ Hz, 1H), 4.25 (s, 2H), 2.63 (s, 3H), 1.76 – 1.67 (m, 2H), 1.51 – 1.42 (m, 2H), 0.98 (t, $J = 7.3$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 167.7, 148.7, 146.4, 128.9, 126.1, 124.2, 117.3, 113.5, 112.7, 64.5, 30.8, 19.2, 15.6, 13.7. ESI-MS m/z (%) 259 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{15}\text{H}_{18}\text{N}_2\text{O}_2$: C, 69.74; H, 7.02; N, 10.84; Found: C, 69.63; H, 7.05; N, 10.90;

(2E)-2,2,2-trifluoroethyl 3-(2-methylH-imidazo[1,2-a]pyridin-3-yl)acrylate (3ad)




^1H NMR (400 MHz, CDCl_3): δ 8.33 (d, $J = 2.7$ Hz, 1H), 8.03 (d, $J = 16.0$ Hz, 1H), 7.68 (s, 1H), 7.36 (s, 1H), 7.02 (s, 1H), 6.26 (d, $J = 16.0$ Hz, 1H), 4.65 (d, $J = 11.1$, 4.5 Hz, 2H), 2.64 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 165.9, 146.9, 131.1, 127.0, 124.5, 117.7, 117.5, 114.0, 109.5, 60.6 ($J = 41.2$ Hz), 15.7. ESI-MS m/z (%) 285 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{13}\text{H}_{14}\text{F}_3\text{N}_2\text{O}_2$: C, 64.93; H, 3.90; N, 9.86; Found: C, 65.04; H, 3.88; N, 9.81;

(2E)-2-ethylhexyl 3-(2-methylH-imidazo[1,2-a]pyridin-3-yl)acrylate (3ae)




^1H NMR (400 MHz, CDCl_3): δ 8.31 (d, $J = 6.8$ Hz, 1H), 7.94 (d, $J = 16.1$ Hz, 1H), 7.64 (d, $J = 8.6$ Hz, 1H), 7.31 (t, $J = 7.8$ Hz, 1H), 6.97 (t, $J = 6.8$ Hz, 1H), 6.24 (d, $J = 16.1$ Hz, 1H), 4.21 – 4.12 (m, 2H), 2.63 (s, 3H), 1.71 – 1.65 (m, 1H), 1.44 – 1.30 (m, 8H), 0.97 – 0.90 (m, 6H). ^{13}C NMR (101 MHz, CDCl_3): δ 167.8, 146.4, 129.0, 126.3, 124.3, 117.4, 113.7, 112.9, 67.1, 39.0, 30.5, 29.0, 23.9, 23.0, 14.1, 11.1. MS (EI) m/z (%): 314, 284, 277, 202, 185, 158, 78. Calcd for $\text{C}_{19}\text{H}_{26}\text{N}_2\text{O}_2$: C, 72.58; H, 8.33; N, 8.91; Found: C, 72.04; H, 8.38; N, 8.97;

(2E)-ethyl 3-(2,8-dimethylH-imidazo[1,2-a]pyridin-3-yl)acrylate (3ba)



^1H NMR (400 MHz, CDCl_3): δ 8.17 (d, $J = 6.8$ Hz, 1H), 7.93 (d, $J = 16.1$ Hz, 1H), 7.10 (d, $J = 6.8$ Hz, 1H), 6.86 (t, $J = 6.9$ Hz, 1H), 6.22 (d, $J = 16.1$ Hz, 1H), 4.29 (q, $J = 7.1$ Hz, 2H), 2.62 (d, $J = 10.2$ Hz, 6H), 1.36 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 167.7, 148.0, 146.6, 129.3, 127.3, 125.4, 122.1, 118.1, 113.5, 112.6, 60.5, 17.0, 15.6, 14.4. MS (EI) m/z (%): 244, 213, 207, 199, 197, 172, 169, 146, 102, 92, 85, 63; ESI-MS m/z (%) 245 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}_2$: C, 68.83; H, 6.60; N, 11.47; Found: C, 68.72; H, 6.62; N, 11.54;


(2E)-butyl 3-(2,8-dimethylH-imidazo[1,2-a]pyridin-3-yl)acrylate (3bc)



^1H NMR (400 MHz, CDCl_3): δ 8.16 (d, $J = 6.8$ Hz, 1H), 7.92 (d, $J = 16.1$ Hz, 1H), 7.09 (d, $J = 6.9$ Hz, 1H), 6.85 (t, $J = 6.9$ Hz, 1H), 6.21 (d, $J = 16.1$ Hz, 1H), 4.22 (t, J


= 6.7 Hz, 2H), 2.62 (d, $J = 9.8$ Hz, 6H), 1.74 – 1.66 (m, 2H), 1.44 (q, $J = 7.5$ Hz, 2H), 0.97 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 167.8, 148.1, 146.7, 129.3, 127.3, 125.4, 122.2, 118.2, 113.5, 112.5, 64.5, 30.9, 19.2, 17.0, 15.6, 13.8. MS (EI) m/z (%): 280, 272, 199, 172, 159, 146, 103, 92, 63. ESI-MS m/z (%) 273 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{16}\text{H}_{20}\text{N}_2\text{O}_2$: C, 70.56; H, 7.04; N, 10.29; Found: C, 70.42; H, 7.07; N, 10.36;

(2E)-2,2,2-trifluoroethyl 3-(2,8-dimethylH-imidazo[1,2-a]pyridin-3-yl)acrylate (3bd)




^1H NMR (400 MHz, CDCl_3): δ 8.18 (d, $J = 6.8$ Hz, 1H), 8.02 (d, $J = 16.0$ Hz, 1H), 7.14 (d, $J = 7.0$ Hz, 1H), 6.90 (t, $J = 6.9$ Hz, 1H), 6.23 (d, $J = 16.0$ Hz, 1H), 4.61 (q, $J = 8.5$ Hz, 2H), 2.64 (d, $J = 12.6$ Hz, 6H), 2.04 (s, 2H). ^{13}C NMR (101 MHz, CDCl_3): δ 166.0, 149.7, 147.2, 131.4, 127.5, 126.1, 122.3 ($J = 140.4$ Hz), 118.1, 113.9, 112.6, 109.1, 60.4 ($J = 16.4$ Hz), 17.0, 15.7. MS (EI) m/z (%): 298, 199, 184, 171, 154, 129, 104, 92, 78, 65; ESI-MS m/z (%) 299 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{14}\text{H}_{13}\text{F}_3\text{N}_2\text{O}_2$: C, 56.38; H, 4.39; N, 9.39; Found: C, 56.49; H, 4.37; N, 9.33;

(2E)-butyl 3-(2,7-dimethylH-imidazo[1,2-a]pyridin-3-yl)acrylate (3cc)



^1H NMR (400 MHz, CDCl_3): δ 8.19 (d, $J = 7.0$ Hz, 1H), 7.91 (d, $J = 16.1$ Hz, 1H), 7.37 (s, 1H), 6.79 (d, $J = 7.0$ Hz, 1H), 6.18 (d, $J = 16.1$ Hz, 1H), 4.24 (t, $J = 6.7$ Hz, 2H), 2.60 (s, 3H), 2.44 (s, 3H), 1.71 (dt, $J = 14.6, 6.8$ Hz, 2H), 1.46 (q, $J = 7.5$ Hz, 2H), 0.98 (q, $J = 5.3$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 167.9, 149.0, 146.9, 137.7, 129.1, 123.7, 116.1, 116.0, 111.6, 64.4, 30.9, 21.3, 19.2, 15.4, 13.8. ESI-MS m/z (%) 273 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{16}\text{H}_{20}\text{N}_2\text{O}_2$: C, 70.56; H, 7.40; N, 10.29; Found: C, 70.42; H, 7.43; N, 10.36;


(2E)-2,2,2-trifluoroethyl 3-(2,7-dimethylH-imidazo[1,2-a]pyridin-3-yl)acrylate (3cd)



^1H NMR (400 MHz, CDCl_3): δ 8.21 (d, $J = 7.0$ Hz, 1H), 8.03 (s, 1H), 7.42 (s, 1H), 6.85 (d, $J = 6.9$ Hz, 1H), 6.20 (d, $J = 16.0$ Hz, 1H), 4.63 (q, $J = 8.5$ Hz, 2H), 2.62 (s, 3H), 2.46 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 171.1, 150.5, 147.5, 138.6, 131.2, 123.9, 117.3 ($J = 171.0$ Hz), 116.5, 108.2, 60.4 ($J = 23.2$ Hz), 21.3, 15.5. MS (EI) m/z (%): 297, 281, 256, 228, 215, 199, 193, 169, 136, 102, 73. ESI-MS m/z (%) 299 (100)


[M+H]⁺. Calcd for C₁₄H₁₃F₃N₂O₂: C, 56.38; H, 4.39; N, 9.39; Found: C, 56.48; H, 4.37; N, 9.34;

(2E)-(tetrahydrofuran-2-yl)methyl 3-(2,7-dimethylH-imidazo[1,2-a]pyridin-3-yl)acrylate (3ce)




¹H NMR (400 MHz, CDCl₃): δ 8.21 (d, *J* = 7.0 Hz, 1H), 7.95 (d, *J* = 16.1 Hz, 1H), 7.38 (s, 1H), 6.80 (d, *J* = 6.9 Hz, 1H), 6.25 (d, *J* = 16.1 Hz, 1H), 4.35 (dd, *J* = 11.2, 3.0 Hz, 1H), 4.23 (q, *J* = 7.1 Hz, 1H), 4.15 (q, *J* = 7.2 Hz, 1H), 3.96 (q, *J* = 6.8 Hz, 1H), 3.90 – 3.84 (m, 1H), 2.60 (s, 3H), 2.45 (s, 3H), 1.99 -1.91 (m, 2H), 1.74 – 1.62 (m, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 167.7, 147.0, 137.8, 129.6, 129.5, 123.7, 116.1, 116.0, 110.9, 68.4, 66.5, 28.0, 25.6, 21.2, 15.4. ESI-MS *m/z* (%) 300 (100) [M+H]⁺. Calcd for C₁₇H₂₀N₂O₃: C, 67.98; H, 6.71; N, 9.33; Found: C, 68.29; H, 6.67; N, 9.26;

(2E)-ethyl 3-(2,5-dimethylH-imidazo[1,2-a]pyridin-3-yl)acrylate (3da)




¹H NMR (400 MHz, CDCl₃): δ 8.06 (s, 1H), 7.89 (d, *J* = 16.1 Hz, 1H), 7.48 (d, *J* = 9.1 Hz, 1H), 7.13 (q, *J* = 9.0 Hz, 1H), 6.19 (d, *J* = 16.1 Hz, 1H), 4.28 (q, *J* = 7.1 Hz, 2H), 2.57 (s, 3H), 2.37 (s, 3H), 1.35 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 167.7, 148.4, 132.9, 129.2, 129.1, 123.4, 122.2, 116.5, 112.3, 60.5, 18.3, 15.5, 14.4. ESI-MS *m/z* (%) 245 (100) [M+H]⁺. Calcd for C₁₄H₁₆N₂O₂: C, 68.83; H, 6.60; N, 11.47; Found: C, 68.70; H, 6.64; N, 11.54;

(2E)-methyl 3-(2,5-dimethylH-imidazo[1,2-a]pyridin-3-yl)acrylate (3db)




¹H NMR (400 MHz, CDCl₃): δ 8.06 (s, 1H), 7.90 (d, *J* = 16.1 Hz, 1H), 7.52 (d, *J* = 9.1 Hz, 1H), 7.15 (d, *J* = 9.0 Hz, 1H), 6.20 (d, *J* = 16.1 Hz, 1H), 3.82 (s, 3H), 2.57 (s, 3H), 2.37 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 168.0, 145.1, 132.9, 129.3, 129.2, 123.5, 122.1, 116.4, 115.7, 111.8, 51.6, 18.2, 15.3. ESI-MS *m/z* (%) 231 (100) [M+H]⁺. Calcd for C₁₃H₁₄N₂O₂: C, 67.81; H, 6.13; N, 12.17; Found: C, 67.70; H, 6.16; N, 12.24;

(2E)-butyl 3-(2,5-dimethylH-imidazo[1,2-a]pyridin-3-yl)acrylate (3dc)




^1H NMR (400 MHz, CDCl_3): δ 8.09 (s, 1H), 7.91 (d, $J = 16.1$ Hz, 1H), 7.55 (d, $J = 9.0$ Hz, 1H), 7.16 (d, $J = 9.0$ Hz, 1H), 6.22 (d, $J = 16.1$ Hz, 1H), 4.25 (t, $J = 6.7$ Hz, 2H), 2.59 (s, 3H), 2.39 (s, 3H), 1.76 – 1.69 (m, 2H), 1.51 – 1.42 (m, 2H), 0.98 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 167.6, 145.0, 129.2, 128.9, 128.8, 123.4, 122.0, 117.3, 116.2, 112.3, 64.2, 30.7, 19.0, 18.1, 15.2, 13.5. ESI-MS m/z (%) 273 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{16}\text{H}_{20}\text{N}_2\text{O}_2$: C, 70.56; H, 7.40; N, 10.29; Found: C, 70.42; H, 7.44; N, 10.35;

(2E)-2,2,2-trifluoroethyl 3-(2,5-dimethylH-imidazo[1,2-a]pyridin-3-yl)acrylate (3dd)




^1H NMR (400 MHz, CDCl_3): δ 8.09 (s, 1H), 8.01 (d, $J = 16.0$ Hz, 1H), 7.52 (d, $J = 8.9$ Hz, 1H), 7.19 (d, $J = 8.9$ Hz, 1H), 6.22 (d, $J = 16.0$ Hz, 1H), 4.63 (q, $J = 8.5$ Hz, 2H), 2.62 (s, 3H), 2.41 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 176.9, 166.1, 150.2, 132.9, 131.2, 129.8, 123.9, 122.5 ($J = 140.0$ Hz), 117.6, 116.8, 108.7, 60.5 ($J = 36.2$ Hz), 29.7, 18.4, 15.7. ESI-MS m/z (%) 299 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{14}\text{H}_{13}\text{F}_3\text{N}_2\text{O}_2$: C, 56.38; H, 4.39; N, 9.39; Found: C, 56.49; H, 4.37; N, 9.34;

ethyl 3-((E)-2-(butoxycarbonyl)vinyl)H-imidazo[1,2-a]pyridine-2-carboxylate(3de)




^1H NMR (400 MHz, CDCl_3): δ 8.48 – 8.37 (m, 2H), 7.78 (d, $J = 9.1$ Hz, 1H), 7.41 – 7.35 (m, 1H), 7.04 (t, $J = 6.9$ Hz, 1H), 6.75 (d, $J = 16.6$ Hz, 1H), 4.50 (q, $J = 7.1$ Hz, 2H), 4.24 (t, $J = 6.7$ Hz, 2H), 1.75 – 1.65 (m, 2H), 1.48 – 1.41 (m, 5H), 0.96 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 166.9, 163.1, 146.0, 137.3, 129.1, 127.4, 125.3, 119.6, 119.4, 118.1, 64.8, 61.6, 30.7, 19.1, 14.3, 13.7. ESI-MS m/z (%) 317 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{17}\text{H}_{20}\text{N}_2\text{O}_4$: C, 64.54; H, 6.37; N, 8.86; Found: C, 64.67; H, 6.39; N, 8.80;

(2Z)-3-(8-methyl-2-phenylH-imidazo [1, 2-a] pyridin-3-yl) acrylonitrile; (2E)-3-(8-methyl-2-phenylH-imidazo [1, 2-a] pyridin-3-yl) acrylonitrile (3dg)




^1H NMR (400 MHz, CDCl_3): δ 8.22 – 8.18 (m, 1.75H), 7.78 – 7.70 (m, 3.75H), 7.56 – 7.49 (m, 5H), 7.46 – 7.39 (m, 1.75H), 7.22 (q, $J = 7.0$ Hz, 1.75H), 7.02 – 6.96 (m, 1.75H), 5.71 – 5.65 (m, 0.75H), 5.60 – 5.53 (m, 1H), 2.74 – 2.70 (m, 5.27H). ^{13}C NMR (100 MHz, CDCl_3): δ 151.19, 149.14, 136.23, 135.88, 133.78, 132.33, 130.93, 129.51, 129.21, 128.97, 128.86, 128.77, 128.14, 126.32, 125.79, 124.27, 122.52, 114.55, 113.23, 94.90, 90.48, 17.17. ESI-MS m/z (%) 184 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{17}\text{H}_{13}\text{N}_3$: C, 78.74; H, 5.05; N, 16.20; Found: C, 78.47; H, 5.13; N, 16.37;

(2E)-3-(6-methyl-imidazo[1,2-a]pyridin-3-yl)acrylonitrile;(2Z)-3-(6-methylH-imidazo[1,2-a]pyridin-3-yl)acrylonitrile(3dh):




^1H NMR (400 MHz, CDCl_3): δ 8.63 (s, 0.6H), 8.02 (d, $J = 7.6$ Hz, 2.6H), 7.93 (s, 0.6H), 7.66 (t, $J = 8.6$ Hz, 1.6H), 7.52 (d, $J = 16.4$ Hz, 1H), 7.23 (d, $J = 10.9$ Hz, 1.6H), 5.78 (d, $J = 16.4$ Hz, 1H), 5.31 (d, $J = 11.9$ Hz, 0.6H), 2.41 (d, $J = 4.8$ Hz). ^{13}C NMR (100 MHz, CDCl_3): δ 137.36, 136.36, 133.92, 133.23, 131.25, 130.09, 124.68, 124.25, 121.61, 120.94, 118.71, 117.83, 91.30, 89.91, 18.44. ESI-MS m/z (%) 184 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{11}\text{H}_{19}\text{N}_3$: C, 72.11; H, 4.95; N, 22.94; Found: C, 71.89; H, 5.01; N, 23.05;

(2E)-ethyl 3-(8-methylH-imidazo[1,2-a]pyridin-3-yl)acrylate (3ea)




^1H NMR (400 MHz, CDCl_3): δ 8.19 (d, $J = 6.7$ Hz, 1H), 8.02 (s, 1H), 7.87 (d, $J = 15.9$ Hz, 1H), 7.13 (d, $J = 6.8$ Hz, 1H), 6.91 (t, $J = 6.9$ Hz, 1H), 6.40 (d, $J = 15.9$ Hz, 1H), 4.32 – 4.26 (m, 2H), 2.64 (s, 3H), 1.35 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 167.2, 149.4, 136.1, 128.7, 128.3, 125.1, 121.9, 114.0, 113.9, 60.5, 16.8, 14.3. ESI-MS m/z (%) 231 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{13}\text{H}_{14}\text{N}_2\text{O}_2$: C, 67.81; H, 6.13; N, 12.17; Found: C, 67.68; H, 6.17; N, 12.26;

(2E)-methyl 3-(8-methylH-imidazo[1,2-a]pyridin-3-yl)acrylate (3eb)




^1H NMR (400 MHz, CDCl_3): δ 8.19 (d, $J = 6.8$ Hz, 1H), 8.07 (s, 1H), 7.87 (d, $J = 15.9$ Hz, 1H), 7.15 (d, $J = 6.8$ Hz, 1H), 6.93 (t, $J = 6.8$ Hz, 1H), 6.42 (d, $J = 15.9$ Hz, 1H), 3.83 (s, 3H), 2.63 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 167.6, 135.5, 128.8, 128.2, 125.7, 125.6, 122.0, 121.9, 114.1, 114.0, 51.8, 20.9, 16.9. ESI-MS m/z (%) 217 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{12}\text{H}_{12}\text{N}_2\text{O}_2$: C, 66.65; H, 5.59; N, 12.96; Found: C, 66.52; H, 5.61; N, 13.04;

(2E)-ethyl 3-(7-methyl-1H-imidazo[1,2-a]pyridin-3-yl)acrylate (3fa)




^1H NMR (400 MHz, CDCl_3): δ 8.22 (d, $J = 6.8$ Hz, 1H), 7.98 (s, 1H), 7.88 (d, $J = 16$ Hz, 1H), 7.47 (s, 1H), 6.85 (d, $J = 7.2$ Hz, 1H), 6.38 (d, $J = 16$ Hz, 1H), 4.32 (q, $J = 7.2$ Hz, 2H), 2.46 (s, 3H), 2.47 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 167.3, 137.6, 137.3, 128.7, 123.5, 117.0, 116.6, 113.2, 60.6, 21.3, 14.4. ESI-MS m/z (%) 231 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{13}\text{H}_{14}\text{N}_2\text{O}_2$: C, 67.81; H, 6.13; N, 12.17; Found: C, 67.70; H, 6.16; N, 12.23;

(2E)-methyl 3-(7-methyl-1H-imidazo[1,2-a]pyridin-3-yl)acrylate (3fb)



^1H NMR (400 MHz, CDCl_3): δ 8.22 (d, $J = 6.8$ Hz, 1H), 7.99 (s, 1H), 7.89 (d, $J = 16$ Hz, 1H), 7.48 (s, 1H), 6.86 (d, $J = 6.8$ Hz, 1H), 6.38 (d, $J = 16$ Hz, 1H), 3.84 (s, 3H), 2.47 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 167.6, 137.7, 137.2, 128.9, 123.4, 117.1, 116.6, 112.8, 51.8, 21.3. ESI-MS m/z (%) 217 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{12}\text{H}_{12}\text{N}_2\text{O}_2$: C, 66.65; H, 5.59; N, 12.96; Found: C, 66.54; H, 5.62; N, 13.02;


(2E)-methyl 3-(6-methyl-1H-imidazo[1,2-a]pyridin-3-yl)acrylate (3gb)



^1H NMR (400 MHz, CDCl_3): δ 8.11 (s, 1H), 8.02 (s, 1H), 7.86 (d, $J = 15.9$ Hz, 1H), 7.69 (d, $J = 9.0$ Hz, 1H), 7.21 (d, $J = 8.7$ Hz, 1H), 6.40 (d, $J = 15.9$ Hz, 1H), 3.84 (s, 3H), 2.41 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 167.7, 149.6, 136.0, 129.8, 128.7,

124.3, 122.0, 117.5, 113.8, 51.9, 18.4. ESI-MS m/z (%) 217 (100) $[M+H]^+$. Calcd for $C_{12}H_{12}N_2O_2$: C, 66.65; H, 5.59; N, 12.96; Found: C, 66.74; H, 5.55; N, 12.88;

(2E)-butyl 3-(6-methylimidazo[1,2-a]pyridin-3-yl)acrylate (3gc)



1H NMR (400 MHz, $CDCl_3$): δ 8.07 (s, 1H), 7.96 (s, 1H), 7.83 (d, $J = 15.9$ Hz, 1H), 7.57 (d, $J = 9.1$ Hz, 1H), 7.14 (d, $J = 9.1$ Hz, 1H), 6.36 (d, $J = 15.9$ Hz, 1H), 4.21 (t, $J = 6.7$ Hz, 2H), 2.38 (s, 3H), 1.72 – 1.65 (m, 2H), 1.43 (q, $J = 7.4$ Hz, 2H), 0.95 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (101 MHz, $CDCl_3$): δ 167.3, 146.9, 136.7, 129.1, 128.5, 123.7, 121.9, 121.3, 117.6, 113.6, 64.4, 30.7, 19.1, 18.3, 13.7. MS (EI) m/z (%): 258, 202, 185, 158, 145, 92, 77, 51; ESI-MS m/z (%) 259 (100) $[M+H]^+$. Calcd for $C_{15}H_{18}N_2O_2$: C, 69.74; H, 7.02; N, 10.84; Found: C, 69.62; H, 7.02; N, 10.91;

